AZ's Onglyza should highlight heart failure risks, FDA panel advises

AstraZeneca ($AZN) dodged a bullet Tuesday, when an FDA panel of experts almost unanimously backed Onglyza's cardiovascular safety. But the committee did recommend that the label of the diabetes therapy feature information about a potential risk of heart failure. More from FiercePharma

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.